Anti-CD47 Reference Antibody (magrolimab)
- Product Code: 139897
Molecular Weight: | Molecular Formula: | ||
---|---|---|---|
EC Number: | MDL Number: | ||
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | -20℃ |
Product Description:
Used in cancer immunotherapy to block the CD47 protein on tumor cells, which helps cancer evade the immune system. By inhibiting CD47, the antibody enables macrophages and other immune cells to recognize and destroy cancer cells. Investigated in clinical trials for hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and non-Hodgkin lymphoma, as well as solid tumors. Often combined with other antibodies like rituximab or azacitidine to enhance anti-tumor activity. Shows potential in promoting phagocytosis and activating adaptive immune responses against cancer.
Sizes / Availability / Pricing:
Size | Availability | Price | Quantity |
---|---|---|---|
50μg | 10-20 days | ฿4,980.00 |
+
-
|
Anti-CD47 Reference Antibody (magrolimab)
Used in cancer immunotherapy to block the CD47 protein on tumor cells, which helps cancer evade the immune system. By inhibiting CD47, the antibody enables macrophages and other immune cells to recognize and destroy cancer cells. Investigated in clinical trials for hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and non-Hodgkin lymphoma, as well as solid tumors. Often combined with other antibodies like rituximab or azacitidine to enhance anti-tumor activity. Shows potential in promoting phagocytosis and activating adaptive immune responses against cancer.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :